Cancer Cure? OX40 TLR9  

  RSS

Jcancom
(@jcancom)
Trusted Member
Joined:1 year  ago
Posts: 51
05/02/2018 5:43 pm  

The recent research using OX40 intratumoral injections and TLR9 cured most mice of various types studied. This is a highly promising approach. The many clinical trials with OX40 now underway are systemically dosing which might not be as effective as an intratumroal dose. However, a new trial is now starting that will use the protocol used in the mice.

This is very exciting! I wish that through the power of social media that the truth about this treatment can be known as soon as possible. It could take many years for this knowledge to be gained if the usual clinical trial process were to be used. In fact the below clinical trial is expected to enroll 15 patients over the next 2 years. We can't wait! We want our lives to live again  NOW! Life should be more than misery. 

https://www.sciencedaily.com/releases/2018/01/180131184751.htm

https://clinicaltrials.gov/ct2/show/NCT03410901


ReplyQuote
veeni
(@veeni)
New Member
Joined:1 year  ago
Posts: 4
06/02/2018 9:55 am  

Jcancom, very good idea to open a new topic, since this treatment deserves its own space in the forum. I can imagine that Head Neck, Skin cancers, Lymphoma, Peritoneal Cancers can be addressed by this treatment very easily. Due to the fact the tumor is artificial.

So I really hope, other companies will open similar trails for other cancers as well. 

But maybe it is not a magic bullet. Bromopyruvate cured also nearly all cancers in mice...


ReplyQuote
Helga
(@helga)
Active Member
Joined:1 year  ago
Posts: 10
06/02/2018 10:03 pm  

Hi J,

Apparently, people did not comply with your wish to move the conversation to here but I do. You are right on, monoclonal antibodies and a lot of immune based therapies are dangerous, cause autoimmune disease, shut down the kidneys, etc. All the more exciting that this ox40/tlr9 ligand combo is safe and less taxing for the immune system. 

Regarding sponsoring by the PI, I doubt he sponsors it from his pocket, more probably from his grant. As you are so enthusiastic and have a high energy to get things done, and seem to be in the US, how about helping this guy with crowd funding?

At the same time, we could also set up a page for Daniel to support this research of his. His articles are immensely informative and more in-depth than anybody else's with practically a layperson's approach but with amazing knowledge and care.

If anybody knows how to proceed about crowd-funding, please respond!

Thanks,

h.


ReplyQuote
Ergin
(@ergin)
Estimable Member
Joined:2 years  ago
Posts: 128
21/02/2018 11:54 am  

Also oleuropein regressed all tumors in all mice in 12 days.And oral usage.You are right Veeni.

But cure only comes when immunity recognizes cancer.


ReplyQuote
Ergin
(@ergin)
Estimable Member
Joined:2 years  ago
Posts: 128
21/02/2018 1:40 pm  

Sorry, only is a big word for cure.

But after treating mice with incvax,They couldnt make cancer again with same type of cancer.


ReplyQuote
dumbcritic
(@dumbcritic)
Active Member
Joined:1 year  ago
Posts: 6
25/02/2018 8:32 pm  

Dr. Williams tweeted this  https://twitter.com/jasonwilliamsmd/status/967073457371598849


ReplyQuote
dumbcritic
(@dumbcritic)
Active Member
Joined:1 year  ago
Posts: 6
25/02/2018 8:49 pm  

Idera Pharma are running a basket trial (NCT03052205) using their TLR9 agonist (IMO-2125) and have treated patients with deep-seated tumours. 

In Cohort 1 (8 mg per injection) eleven have been dosed and all completed the 21 day dose limiting toxicities period. No DLTs or other safety concerns have occurred. The types of cancers treated are: pancreatic (n=6), ocular melanoma (n=1), colorectal (n=1), chondrosarcoma (n=1), breast (n=1) and esophageal (n=1). Eight of these had their liver lesions injected. Now Cohort 2 (16 mg per injection) is enrolling.

Three patients in Cohort 1 continue to be treated and investigator assessments indicate stable disease in two (pancreatic & colorectal) under RECIST and another has stable disease (pancreatic) under irRECIST http://www.irrecist.com/


ReplyQuote
marcosbomber901
(@marcosbomber901)
Active Member
Joined:1 year  ago
Posts: 10
27/02/2018 5:53 pm  

https://twitter.com/jasonwillia.../status/967073457371598849

Dr. Jason Williams already incorporates in its crioablation protocol of the TLR9 agonist and anti OX40


Daniel liked
ReplyQuote
marcosbomber901
(@marcosbomber901)
Active Member
Joined:1 year  ago
Posts: 10
27/02/2018 5:54 pm  

 The only TLR 7/8 agonist that's in a PhI is MEDI9197  http://cancerres.aacrjournals.org/.../77/13_Supplement/CT091  Based on preclinical data it could be combine with either SD-101 or IMO-2125 (TLR 9 agonists)  https://jitc.biomedcentral.com/art.../10.1186/2051-1426-2-12 Nektar plan to test NKTR-262 plus NKTR-214 in the next few months  http://www.nektar.com/.../NKTR-262-NKTR-214__2017SITC...  Some of these drugs could be available via right-to-try.


ReplyQuote
Daniel
(@daniel)
Estimable Member Admin
Joined:3 years  ago
Posts: 123
27/02/2018 11:53 pm  

Thanks! Interesting!


ReplyQuote
dumbcritic
(@dumbcritic)
Active Member
Joined:1 year  ago
Posts: 6
02/03/2018 10:40 pm  

The PhI/II of NKTR-262 will be open soon  https://clinicaltrials.gov/ct2/show/NCT03435640  Initial data will be presented in the second half and I assume (rightly or wrongly) at a conference (SITC/ESMO).

 

Idera's TLR9 (IMO-2125) is now in a PhIII  https://clinicaltrials.gov/ct2/show/NCT03445533 and SD-101 by Dynavax should be by the end of this year. It will be tested in newly diagnosed advanced melanoma patients in combo with Pembrolizumab (anti-PD1). The TLR4 agonist (G100) by Immune Design could be as well. Assuming the FDA grant this then they will be targeting relapsed/refractory (post anti-CD20) follicular NHL.


veeni liked
ReplyQuote
Share: